PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the ARV-471 (PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT05463952
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa, Chiba, Japan
Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05462639
- Locations
- 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Hematology/Oncology - Westwood (Building 200 Suite 120), Los Angeles, California, United States
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- Conditions
- Pneumonia
- Interventions
- Diagnostic Test: Diagnostic test on urine samples
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12500
- Registration Number
- NCT05452941
- Locations
- 🇪🇸
Hospital Universitari i Politecnic La Fe, Valencia, València, Spain
🇺🇸Kaiser Permanete Baldwin Park, Baldwin Park, California, United States
🇺🇸Kaiser Permanete Downey, Downey, California, United States
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
- Conditions
- Breast Cancer
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1054
- Registration Number
- NCT05452798
- Locations
- 🇩🇰
Danish Breast Cancer Group, Copenhagen, Denmark
A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05446142
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study to Learn About the Medicine (PF-07321332 or Nirmatrelvir/Ritonavir) in Healthy Lactating Women
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT05441215
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77814
- Registration Number
- NCT05438888
- Locations
- 🇯🇵
Pfizer Site, Tokyo, Japan
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 157
- Registration Number
- NCT05438602
- Locations
- 🇨🇦
Diex Recherche Sherbrooke Inc., Sherbrooke, Quebec, Canada
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇧🇷IBPClin - Instituto Brasil de Pesquisa Clínica, Rio de Janeiro, Brazil
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05434091
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 429
- Registration Number
- NCT05431088
- Locations
- 🇺🇸
LSU Health Baton Rouge-North Clinic, Baton Rouge, Louisiana, United States
🇺🇸Our Lady of the Lake Hopistal, Inc, Baton Rouge, Louisiana, United States
🇺🇸Our lady of the Lake Hospital, Baton Rouge, Louisiana, United States